Archive | August, 2017

CMP Pharma Announces FDA Approval of CaroSpir® (Spironolactone Oral Suspension, 25mg/5mL)

CMP Pharma announced that the US Food and Drug Administration (FDA) has granted final approval of the company’s New Drug Application (NDA) for CaroSpir® (Spironolactone Oral Suspension, 25 mg/5mL), the first and only FDA-approved oral liquid dosage form of the potassium-sparing diuretic spironolactone. “CaroSpir® provides a stable, ready to use and consistent liquid treatment option […]